Bepirovirsen reaches functional cure in about 1 in 5 hepatitis B patients in Phase 3
An article on two Phase 3 trials reports that the drug bepirovirsen, from GSK and Ionis, led to a functional cure of hepatitis B in about 1 in 5 patients.
Source: Bepirovirsen shows functional cure in about 1 in 5 hepatitis B patients in Phase 3 (x.com). Summary written with AI from the source and reviewed by rules; read the original.
What the research shows
According to the article, two Phase 3 clinical trials, conducted in people, tested the drug bepirovirsen, developed by GSK and Ionis. In about 1 in 5 participants, a functional cure was observed, defined by the disappearance of the hepatitis B surface antigen and the development of protective antibodies. The text also mentions claims of higher rates in certain groups, but that passage is incomplete, so those figures cannot be detailed here.
A functional cure differs from complete elimination of the virus, but it indicates that the infection can stay controlled in some patients. According to the article, this could mean that, in some cases, the disease could be controlled without long-term antiviral drugs. Phase 3 trials are advanced stages of research, but results from a study still need to be confirmed by other studies over time before they become standard clinical practice.
What it means
The result suggests that a treatment could, in some patients, lead to lasting control of hepatitis B. It is still unknown how long this effect lasts, who benefits most, and what side effects appear over the long term.
How to read it with care
This result does not replace a medical consultation. Anyone who has hepatitis B or is considering changes to treatment, diet or supplements should talk to a doctor or another qualified health professional.